Ruediger Rueger
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
-
- Melanoma and MAPK Pathways
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
Papers in
-
- Melanoma and MAPK Pathways 6
- Protein Degradation and Inhibitors 2
- Oncology 6
- Cancer-related Molecular Pathways 4
- Colorectal Cancer Treatments and Studies 1
- Cytokine Signaling Pathways and Interactions 1
- Co-authors
- Jianguo Zhi (3 shared papers)Gwen Nichols (3 shared papers)Florian Heil (2 shared papers)Nicolas Penel (2 shared papers)Jean‐Yves Blay (2 shared papers)Lyubomir T. Vassilev (2 shared papers)Antoîne Italiano (2 shared papers)David Geho (1 shared paper)
- Journals
- Clinical Cancer Research (3 papers)Molecular Cancer Therapeutics (2 papers)Journal of Clinical Oncology (2 papers)Applied immunohistochemistry & molecular morphology (1 paper)The Journal of Clinical Pharmacology (1 paper)
- Partner nations
- SwitzerlandUnited StatesFrance
In The Last Decade
Ruediger Rueger
12 papers receiving 763 citations
Ruediger Rueger's Hit Papers
Peers
Comparison fields: 5 of 64
- Oncology 422
- Molecular Biology 500
- Pulmonary and Respiratory Medicine 215
- Cancer Research 93
- Pathology and Forensic Medicine 98
Countries citing papers authored by Ruediger Rueger
This map shows the geographic impact of Ruediger Rueger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruediger Rueger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruediger Rueger more than expected).
Fields of papers citing papers by Ruediger Rueger
This network shows the impact of papers produced by Ruediger Rueger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruediger Rueger. The network helps show where Ruediger Rueger may publish in the future.
Co-authors
The 25 scholars most cited alongside Ruediger Rueger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study Hit paper breakdown → | 2012 | 455 |
| 2 | 2012 | 122 | |
| 3 | 2012 | 55 | |
| 4 | 2015 | 41 | |
| 5 | 2009 | 30 | |
| 6 | 2009 | 18 | |
| 7 | 2010 | 15 | |
| 8 | 2011 | 10 | |
| 9 | 2017 | 8 | |
| 10 | 2010 | 8 | |
| 11 | 2011 | 6 | |
| 12 | 2010 | 1 |
About Ruediger Rueger
Ruediger Rueger is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Computational Theory and Mathematics, having authored 12 papers that have together received 769 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (6 papers), Cancer-related Molecular Pathways (4 papers), Sarcoma Diagnosis and Treatment (3 papers), Computational Drug Discovery Methods (2 papers), Protein Degradation and Inhibitors (2 papers), Colorectal Cancer Treatments and Studies (1 paper), Cytokine Signaling Pathways and Interactions (1 paper) and Cell Image Analysis Techniques (1 paper). The work is most often cited by research in Oncology (422 citations), Molecular Biology (500 citations), Pulmonary and Respiratory Medicine (215 citations), Cancer Research (93 citations) and Pathology and Forensic Medicine (98 citations). Ruediger Rueger has collaborated with scholars based in Switzerland, United States and France. Frequent co-authors include Jianguo Zhi, Gwen Nichols, Florian Heil, Nicolas Penel, Jean‐Yves Blay, Lyubomir T. Vassilev, Antoîne Italiano, David Geho, Isabelle Ray‐Coquard and Binh Bui. Their work appears in journals such as Clinical Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology, Applied immunohistochemistry & molecular morphology and The Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.